Cytovation

18 articles about Cytovation

• Cytovation Announces Appointment of Ellen Lubman, MBA to its Board of Directors

  12/20/2023

  Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumour membrane immunotherapy CyPep-1, announced the election of Ellen Lubman, MBA, to its Board of Directors.

• Cytovation Reports Promising Interim Results from Phase 1/2a CICILIA Study with CyPep-1 in Solid Tumors

  10/11/2023

  Cytovation ASA, a clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class, dual-acting targeted tumor immunotherapy, announces positive initial data from Part 2 of its Phase 1/2a CICILIA basket trial with all trial endpoints met.

• Cytovation appoints Olav Hellebø to its Board of Directors

  7/5/2023

  Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces the appointment of Olav Hellebø to its Board of Directors.

• Cytovation raises $8 million in Series A extension financing round for clinical advancement of CyPep-1, a first-in-class targeted tumor membrane immunotherapy

  6/2/2023

  Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces the successful closing of its $8 million Series A extension financing round.

• Cytovation appoints Iman Barilero as Chief Development Officer

  3/21/2023

  Bergen, Norway, 21 March 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces that Dr. Iman Barilero has joined the company as Chief Development Officer.

• Cytovation announces first patient dosed in Phase 2a study investigating CyPep-1 monotherapy in advanced melanoma refractory to checkpoint inhibitors

  2/15/2023

  Cytovation ASA announces that the first patient has been dosed in its Phase 2a study investigating CyPep-1 monotherapy in patients with advanced melanoma refractory to checkpoint inhibitors.

• 

  Global Roundup: Celltrion Prepares to Trap COVID-19 in Phase III

  2/10/2022

  Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
• 

  Global Roundup: Norway's Cytovation Snags $20 Million in a Series A

  1/27/2022

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
• 

  Global Roundup: Galapagos NV Wins European Approval for Ulcerative Colitis Therapy

  11/18/2021

  Biopharma and life sciences companies from across the globe provide updates. Belgium-based Galapagos NV won European approval for Jyseleca for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
• 

  BioSpace Movers & Shakers, Oct. 29

  10/29/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
• 

  BioSpace Global Roundup, Aug. 15

  8/15/2019

  Biopharma companies from across the globe provide updates on their pipeline and business.

• Cytovation and SMS-oncology sign agreement on conduct of phase I/II trial with CyPep-1 in solid tumors

  8/9/2019

  Cytovation AS and Specialized Medical Services-oncology BV announce that SMS-oncology has been selected as the CRO to conduct the phase I/II clinical trial with CyPep-1 in patients with advanced solid cancers.

• 

  BioSpace's Global Biopharma Roundup: March 21

  3/21/2019

  Biotech and pharma companies from across Europe and Asia provide updates on pipeline and business activities.

• Cytovation Initiates Clinical Development Programme With CyPep-1, a First-in-class Lytic Agent for Tumor Immunotherapy

  3/18/2019

  First patients treated in a Phase I study with CyPep-1 as an investigational therapy for benign, HPV-induced cutaneous tumors (warts)

• Cytovation Completes NOK 30m Financing Round to Progress Cypep-H1 Through Phase I/IIa Clinical Study in Cutaneous Warts

  1/8/2018

  Cytovation announces it has raised NOK 10m in a private funding round, completing the second stage of fundraising, having raised NOK 20m in June 2017.

• Cytovation Announces Private Fundraising Round Of NOK 20m To Progress Cypep-1 To Phase I Clinical Study

  6/29/2017

• Cytovation Announces Private Fundraising Round Of NOK 20m To Progress Cypep-1 To Phase I Clinical Study

  6/29/2017

• Cytovation Release: Company Announces Appointment Of Ole-Erik Iversen As Scientific Advisor

  1/20/2017